About Cellectis (NASDAQ:CLLS)
Cellectis S.A., a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL). The company's products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-ALL. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc; Les Laboratoires Servier SAS; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Trailing P/E Ratio-10.69
Forward P/E Ratio-11.34
Sales & Book Value
Annual Sales$33.72 million
Price / Sales36.65
Price / CashN/A
Book Value$7.96 per share
Price / Book3.73
EPS (Most Recent Fiscal Year)($2.78)
Return on Equity-35.63%
Return on Assets-30.10%
Cellectis (NASDAQ:CLLS) Frequently Asked Questions
What is Cellectis' stock symbol?
Cellectis trades on the NASDAQ under the ticker symbol "CLLS."
How were Cellectis' earnings last quarter?
Cellectis (NASDAQ:CLLS) posted its earnings results on Monday, March, 12th. The biotechnology company reported ($0.76) earnings per share for the quarter, missing analysts' consensus estimates of ($0.64) by $0.12. The biotechnology company had revenue of $6.91 million for the quarter, compared to analysts' expectations of $10.10 million. Cellectis had a negative return on equity of 35.63% and a negative net margin of 298.01%. View Cellectis' Earnings History.
When is Cellectis' next earnings date?
What price target have analysts set for CLLS?
6 equities research analysts have issued 1-year price objectives for Cellectis' stock. Their predictions range from $20.00 to $73.00. On average, they expect Cellectis' stock price to reach $44.00 in the next year. View Analyst Ratings for Cellectis.
Who are some of Cellectis' key competitors?
Some companies that are related to Cellectis include Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Sangamo Therapeutics (SGMO), Repligen (RGEN), Acceleron Pharma (XLRN), Editas Medicine (EDIT), Momenta Pharmaceuticals (MNTA), Atara Biotherapeutics (ATRA), Audentes Therapeutics (BOLD), DBV Technologies (DBVT), Iovance Biotherapeutics (IOVA), REGENXBIO (RGNX), Adaptimmune Therapeutics (ADAP), Acorda Therapeutics (ACOR), Bavarian Nordic (BVNRY), La Jolla Pharmaceutical (LJPC), Coherus BioSciences (CHRS) and Novavax (NVAX).
Who are Cellectis' key executives?
Cellectis' management team includes the folowing people:
- Dr. André Choulika Ph.D., Co-Founder, Chairman and Chief Exec. Officer (Age 53)
- Dr. David J. D. Sourdive Ph.D., Co-Founder, Exec. VP - Technical Operations and Director (Age 51)
- Mr. Eric Dutang, Chief Financial Officer (Age 44)
- Ms. Elsy Boglioli, Chief Operating Officer
- Dr. Philippe Duchateau Ph.D., Chief Scientific Officer (Age 55)
When did Cellectis IPO?
(CLLS) raised $129 million in an initial public offering on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray served as the underwriters for the IPO and Oppenheimer was co-manager.
Has Cellectis been receiving favorable news coverage?
Press coverage about CLLS stock has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cellectis earned a media sentiment score of 0.03 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 46.07 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
How do I buy shares of Cellectis?
Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cellectis' stock price today?
One share of CLLS stock can currently be purchased for approximately $29.71.
How big of a company is Cellectis?
Cellectis has a market capitalization of $1.24 billion and generates $33.72 million in revenue each year. The biotechnology company earns $-99,360,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis. Cellectis employs 122 workers across the globe.
How can I contact Cellectis?
Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS LLE-DE-FRANCE I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]
MarketBeat Community Rating for Cellectis (CLLS)MarketBeat's community ratings are surveys of what our community members think about Cellectis and other stocks. Vote "Outperform" if you believe CLLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cellectis (NASDAQ:CLLS) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Cellectis (NASDAQ CLLS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 16.41%
Institutional Ownership Percentage: 20.30%
Cellectis (NASDAQ CLLS) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
Cellectis (NASDAQ CLLS) News Headlines
|Should Cellectis SA.’s (EPA:ALCLS) Recent Earnings Decline Worry You?|
finance.yahoo.com - April 18 at 8:43 AM
|Cellectis (CLLS) Downgraded by BidaskClub to "Hold"|
www.americanbankingnews.com - April 16 at 10:55 AM
|Zacks: Analysts Anticipate Cellectis (CLLS) Will Announce Quarterly Sales of $9.53 Million|
www.americanbankingnews.com - April 16 at 4:58 AM
|Cellectis (CLLS) Given Average Rating of "Hold" by Analysts|
www.americanbankingnews.com - April 15 at 1:39 AM
|Cellectis (CLLS) Stock Rating Lowered by BidaskClub|
www.americanbankingnews.com - April 14 at 6:22 PM
| Brokerages Anticipate Cellectis (CLLS) Will Post Earnings of -$0.66 Per Share|
www.americanbankingnews.com - April 14 at 3:17 AM
|What Should We Expect From Cellectis SA.’s (NASDAQ:CLLS) Earnings Over The Next Few Years?|
finance.yahoo.com - April 13 at 8:55 AM
|Cellectis Announces Closing of Follow-On Offering|
finance.yahoo.com - April 10 at 5:09 PM
|Cellectis (CLLS) Earns Buy Rating from Jefferies Group|
www.americanbankingnews.com - April 8 at 8:06 PM
|Is Cellectis SA Stock a Buy Now?|
finance.yahoo.com - April 7 at 9:04 AM
|Can Been-There Biotech Entrepreneur Arie Belldegrun Do It Yet Again?|
finance.yahoo.com - April 6 at 8:55 AM
|Cellectis: Monthly Information on Share Capital and Company Voting Rights|
www.businesswire.com - April 5 at 4:59 PM
|Why Micron Technology, Mechel, and Cellectis Slumped Today|
finance.yahoo.com - April 5 at 4:59 PM
|Cellectis (CLLS) Announces Launch of $175M Follow-On Offering|
www.streetinsider.com - April 5 at 10:47 AM
|Cellectis down 2% premarket on pricing of follow-on offering|
seekingalpha.com - April 5 at 10:47 AM
|Cellectis (CLLS) Upgraded to Buy at ValuEngine|
www.americanbankingnews.com - April 3 at 5:52 PM
|Cellectis to continue CAR T collaboration with Allogene; shares up 18%|
seekingalpha.com - April 3 at 5:09 PM
|Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate ...|
www.businesswire.com - April 3 at 8:53 AM
|Cellectis, Allogene To Continue Strategic Cancer Immunotherapy Collaboration|
www.nasdaq.com - April 3 at 8:53 AM
|Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies|
finance.yahoo.com - April 3 at 8:53 AM
|Cellectis (CLLS) Stock Rating Upgraded by BidaskClub|
www.americanbankingnews.com - March 30 at 6:14 PM
|Zacks: Analysts Anticipate Cellectis SA (CLLS) Will Announce Earnings of -$0.66 Per Share|
www.americanbankingnews.com - March 28 at 3:08 AM
|BidaskClub Lowers Cellectis (CLLS) to Buy|
www.americanbankingnews.com - March 28 at 12:34 AM
|Cellectis (CLLS) Rating Increased to Strong-Buy at BidaskClub|
www.americanbankingnews.com - March 26 at 9:57 AM
|Cellectis (CLLS) Stock Rating Upgraded by ValuEngine|
www.americanbankingnews.com - March 25 at 7:32 PM
|Cellectis (CLLS) Downgraded to "Hold" at BidaskClub|
www.americanbankingnews.com - March 23 at 11:20 PM
|Cellectis SA (CLLS) Receives Consensus Rating of "Hold" from Analysts|
www.americanbankingnews.com - March 21 at 3:46 AM
|What Should Investors Know About Cellectis SA.’s (EPA:ALCLS) Earnings Trend?|
finance.yahoo.com - March 19 at 8:52 AM
|Cellectis (CLLS) Coverage Initiated by Analysts at Guggenheim|
www.americanbankingnews.com - March 16 at 2:54 PM
|Research Analysts Offer Predictions for Cellectis SA's Q1 2018 Earnings (CLLS)|
www.americanbankingnews.com - March 16 at 8:37 AM
|Cellectis SA Forecasted to Earn Q1 2018 Earnings of ($0.59) Per Share (CLLS)|
www.americanbankingnews.com - March 16 at 8:36 AM
|Cellectis SA to Post FY2022 Earnings of ($3.89) Per Share, Oppenheimer Forecasts (CLLS)|
www.americanbankingnews.com - March 15 at 3:10 PM
|SunTrust Banks Weighs in on Cellectis SA's FY2022 Earnings (CLLS)|
www.americanbankingnews.com - March 15 at 3:10 PM
|Cellectis SA (CLLS) to Post Q4 2018 Earnings of ($0.67) Per Share, Jefferies Group Forecasts|
www.americanbankingnews.com - March 15 at 11:28 AM
|Report: Exploring Fundamental Drivers Behind Mountain Province Diamonds, Limoneira, Arsanis, ExlService, Argo Group International, and Cellectis S.A. — New Horizons, Emerging Trends, and Upcoming Developments|
finance.yahoo.com - March 15 at 8:41 AM
|Cellectis (CLLS) Downgraded by BidaskClub to Buy|
www.americanbankingnews.com - March 14 at 7:51 PM
|Nomura Increases Cellectis (CLLS) Price Target to $73.00|
www.americanbankingnews.com - March 14 at 4:44 PM
|Dr. Mathieu Simon to Retire as Cellectis’ Chief Operating Officer; Elsy Boglioli Named as Successor|
finance.yahoo.com - March 13 at 6:57 PM
|Cellectis SA.’s (NASDAQ:CLLS) Profit Outlook|
finance.yahoo.com - March 13 at 8:55 AM
|Cellectis Reports 4th Quarter and Full Year 2017 Financial Results|
finance.yahoo.com - March 12 at 6:13 PM
|Cellectis: Servier and Pfizer Announce Results of UCART19 First-in-Human Trials to Be Presented at the 44th EBMT (European Society for Blood and Marrow Transplantation) Annual Meeting|
finance.yahoo.com - March 8 at 6:10 PM
|[$$] Crispr gene editing ready for testing in humans|
finance.yahoo.com - March 5 at 8:44 AM
|40,000 Shares in Cellectis SA (CLLS) Acquired by Hudson Bay Capital Management LP|
www.americanbankingnews.com - March 3 at 12:50 PM
|Cellectis SA (CLLS) Stake Lifted by ARK Investment Management LLC|
www.americanbankingnews.com - February 27 at 4:24 AM
|Zacks: Analysts Expect Cellectis SA (CLLS) Will Announce Quarterly Sales of $10.10 Million|
www.americanbankingnews.com - February 24 at 9:28 AM
|Cellectis SA (CLLS) Receives Consensus Recommendation of "Buy" from Brokerages|
www.americanbankingnews.com - February 24 at 3:58 AM
| Analysts Expect Cellectis SA (CLLS) Will Post Earnings of -$0.64 Per Share|
www.americanbankingnews.com - February 22 at 3:12 AM
|BidaskClub Upgrades Cellectis (CLLS) to Strong-Buy|
www.americanbankingnews.com - February 17 at 1:40 PM
|Cellectis (CLLS) Downgraded by Zacks Investment Research to Sell|
www.americanbankingnews.com - February 14 at 8:18 PM
|Financial Analysis: Cellectis (CLLS) vs. Zynerba Pharmaceuticals (ZYNE)|
www.americanbankingnews.com - February 13 at 9:12 PM
Cellectis (NASDAQ:CLLS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Cellectis (NASDAQ:CLLS) Income Statement, Balance Sheet and Cash Flow Statement
Cellectis (NASDAQ CLLS) Stock Chart for Sunday, April, 22, 2018